International Journal of Pharmaceutical Research and Applications
Volume 9, Issue 5 Sep - Oct 2024, pp: 13-17 www.ijprajournal.com ISSN: 2456-4494

Adverse Drug Reactions and Pharmacovigilance: An Overview

Seema Mishra[*], Dr. Nilam Nigam[*], Dr.Shrawan Kumar[**], Dr. Kriti Jalota[*], Dr. Archana[**], Dr. Syed Shadman Ahmad[*], Praveen Katiyar[***]

** Department of Pharmacology Rama Medical College Hospital and Research Centre Mandhana, Kanpur*
** *Department of General MedicineRama Medical College Hospital and Research Centre, Mandhana, Kanpur*
**** Chief Proctor C S J M University, Kanpur*

Date of Submission: 01-09-2024 Date of Acceptance: 10-09-2024

ABSTRACT
Adverse drug reactions (ADRs) pose a significant challenge in clinical practice and public health, contributing to morbidity, mortality, and increased healthcare costs. Pharmacovigilance plays a critical role in identifying, evaluating, and mitigating the risks associated with ADRs, thereby enhancing patient safety and drug efficacy. This review provides a comprehensive overview of the classification, mechanisms, and clinical implications of ADRs, along with a detailed exploration of pharmacovigilance systems worldwide. Emphasis is placed on the need for proactive pharmacovigilance, the role of healthcare professionals, and recent advancements in ADR reporting technologies.

Key Words- Adverse drug reactions, Pharmacovigilance

I. INTRODUCTION

Adverse drug reactions (ADRs) are a common cause of hospital admissions and a significant contributor to patient morbidity and mortality. An ADR is defined by the World Health Organization (WHO) as "a response to a drug which is noxious and unintended, and which occurs at doses normally used in man for the prophylaxis, diagnosis, or therapy of disease, or for the modification of physiological function" [1]. The need to monitor, assess, and prevent ADRs has given rise to the field of pharmacovigilance, which encompasses the processes involved in detecting and evaluating ADRs to ensure drug safety [2]. This review aims to explore the types, mechanisms, clinical implications of ADRs, and the importance of pharmacovigilance in promoting safer drug use.

Types of Adverse Drug Reactions

ADRs are broadly classified into two categories:

1. **Type A (Augmented) Reactions**: These are dose-dependent reactions and are usually predictable based on the pharmacological action of the drug. Examples include hypoglycemia from insulin and bleeding from anticoagulants [3].
2. **Type B (Bizarre) Reactions**: These reactions are not dose-dependent and are often unpredictable, such as anaphylaxis from penicillin [4]. They are generally more severe and occur less frequently than Type A reactions.

Other classifications of ADRs have been proposed, including:

- **Type C (Chronic)**: Reactions that occur after prolonged drug use, such as osteoporosis from long-term corticosteroid therapy.
- **Type D (Delayed)**: Reactions that manifest after a long period, such as carcinogenesis from chemotherapeutic agents.
- **Type E (End of use)**: Withdrawal reactions, such as opioid withdrawal syndrome.
- **Type F (Failure)**: Treatment failure due to drug interactions or resistance, often seen in antimicrobial therapy [5].

Mechanisms of Adverse Drug Reactions

The mechanisms underlying ADRs can be pharmacological, immunological, or genetic. Understanding these mechanisms helps clinicians predict and prevent certain reactions.

Pharmacological Mechanisms

Most Type A ADRs are pharmacological and occur when the drug's effect is exaggerated. For example, excessive vasodilation from antihypertensive medications can cause hypotension, while too much insulin leads to hypoglycemia [6].

Immunological Mechanisms

Type B ADRs often result from immune-mediated hypersensitivity reactions. These can be classified as:

International Journal of Pharmaceutical Research and Applications
Volume 9, Issue 5 Sep - Oct 2024, pp: 13-17 www.ijprajournal.com ISSN: 2456-4494

- **Type I (Immediate hypersensitivity)**: IgE-mediated reactions, such as anaphylaxis.
- **Type II (Cytotoxic reactions)**: IgG or IgM-mediated reactions leading to cell lysis, such as drug-induced hemolyticanemia.
- **Type III (Immune complex reactions)**: Involves immune complexes that deposit in tissues, causing conditions like serum sickness.
- **Type IV (Delayed-type hypersensitivity)**: T-cell-mediated reactions, such as contact dermatitis [7].

Genetic Mechanisms

Genetic polymorphisms in drug-metabolizing enzymes, transporters, or receptors can predispose individuals to ADRs. For example, polymorphisms in the cytochrome P450 enzyme system (CYP2D6) can alter drug metabolism, leading to toxic levels of drugs such as codeine or tamoxifen [8].

Clinical Implications of Adverse Drug Reactions

ADRs can range from mild to life-threatening and can affect any organ system. They contribute significantly to hospital admissions and healthcare costs. The clinical implications of ADRs include:

- **Increased Morbidity and Mortality**: ADRs are associated with prolonged hospital stays, increased patient morbidity, and, in severe cases, death. A study estimated that ADRs are responsible for 6-7% of hospital admissions and up to 0.1-0.3% of hospital mortality [9].
- **Economic Burden**: ADRs significantly increase healthcare costs, not only due to additional treatment but also from the need for monitoring and managing drug-related complications. In the United States, the cost of ADR-related hospitalizations is estimated to be billions of dollars annually [10].
- **Impact on Drug Compliance**: ADRs, especially those that cause discomfort or inconvenience, can lead to poor patient compliance, thus diminishing the effectiveness of treatment [11].

Pharmacovigilance: Definition and Importance

Pharmacovigilance is defined by the WHO as "the science and activities relating to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problem" [12]. It plays a critical role in ensuring patient safety by identifying previously unrecognized ADRs and changes in drug safety profiles.

Key Objectives of Pharmacovigilance

- **Early Detection of ADRs**: Pharmacovigilance systems aim to detect new, rare, and serious ADRs that may not have been evident during clinical trials [13].
- **Risk-Benefit Analysis**: By continuously assessing the risk-benefit ratio of drugs, pharmacovigilance helps in making informed decisions about drug withdrawals or modifications in prescribing information.
- **Improvement in Patient Safety**: Pharmacovigilance contributes to better patient outcomes by reducing the incidence of ADRs and ensuring that the benefits of drugs outweigh the risks [14].

Pharmacovigilance Systems Around the World

Different countries have established pharmacovigilance systems, with varying levels of integration and effectiveness.

WHO Program for International Drug Monitoring

The WHO initiated its Program for International Drug Monitoring (PIDM) in response to the thalidomide disaster in the 1960s. The program operates through a global network of national pharmacovigilance centers that report ADRs to the WHO Uppsala Monitoring Centre (UMC) [15]. The UMC manages the global ADR database, VigiBase, which contains millions of ADR reports and serves as a valuable resource for drug safety monitoring [16].

Pharmacovigilance in Europe

The European Medicines Agency (EMA) oversees pharmacovigilance in the European Union (EU). The EU's pharmacovigilance system requires marketing authorization holders to continuously monitor and report ADRs. The EudraVigilance database is the central repository for ADR reports within the EU [17].

Pharmacovigilance in the United States

The United States Food and Drug Administration (FDA) operates the MedWatch program, which allows healthcare professionals and patients to report ADRs. The FDA's Adverse Event Reporting System (FAERS) is a critical tool for monitoring drug safety in the post-marketing phase [18].

International Journal of Pharmaceutical Research and Applications
Volume 9, Issue 5 Sep - Oct 2024, pp: 13-17 www.ijprajournal.com ISSN: 2456-4494

Pharmacovigilance in India

In India, the Pharmacovigilance Program of India (PvPI) was launched in 2010 under the supervision of the Central Drugs Standard Control Organization (CDSCO). The PvPI collects and analyzes ADRs through a network of Adverse Drug Reaction Monitoring Centres (AMCs) across the country. India is also a member of the WHO PIDM [19].

Challenges in Pharmacovigilance

Despite the importance of pharmacovigilance, several challenges limit its effectiveness.

Underreporting of ADRs

One of the major challenges in pharmacovigilance is the underreporting of ADRs. Studies suggest that only 6-10% of serious ADRs are reported. This underreporting can be attributed to various factors, including a lack of awareness among healthcare professionals, the voluntary nature of reporting systems, and fear of legal repercussions [20].

Data Quality and Standardization

The data reported to pharmacovigilance systems can sometimes be incomplete or lack standardization, which hampers the ability to detect safety signals. Efforts to harmonize ADR reporting across different countries and regions are ongoing [21].

Emerging Therapeutics

With the advent of novel therapeutics such as biologics and gene therapies, new challenges have emerged in pharmacovigilance. These therapies may have unique ADR profiles that require specialized monitoring systems [22].

Advancements in Pharmacovigilance

Technological advancements have revolutionized pharmacovigilance, making it more efficient and effective.

Artificial Intelligence and Machine Learning

Artificial intelligence (AI) and machine learning (ML) are increasingly being used to analyze large volumes of ADR data. These technologies can detect patterns and identify potential ADRs faster than traditional methods. For example, AI is being used to mine electronic health records and social media for unreported ADRs [23].

Electronic Health Records

The integration of pharmacovigilance systems with electronic health records (EHRs) has facilitated the real-time detection of ADRs. Automated algorithms can scan EHRs for abnormal lab results or drug interactions, triggering alerts for potential ADRs [24].

Mobile Applications

Several mobile applications have been developed to encourage ADR reporting by healthcare professionals and patients. These apps simplify the reporting process and can help increase the number of ADRs reported [25].

The Role of Healthcare Professionals in Pharmacovigilance

Healthcare professionals play a pivotal role in the pharmacovigilance system. They are often the first to detect and report ADRs, making their participation crucial for the success of pharmacovigilance programs.

Pharmacists

Pharmacists are in a unique position to identify ADRs, especially in outpatient settings. They can counsel patients on potential ADRs and encourage them to report any unexpected reactions [26].

Physicians

Physicians are responsible for diagnosing and managing ADRs. They should remain vigilant for any signs of ADRs and report them promptly to pharmacovigilance authorities [27].

Nurses

Nurses, particularly in hospital settings, are often the first to observe ADRs. Their role in patient monitoring and care makes them key contributors to pharmacovigilance [28].

II. CONCLUSION

Adverse drug reactions are a significant public health concern, leading to increased morbidity, mortality, and healthcare costs. Pharmacovigilance systems are essential for monitoring and mitigating the risks associated with drug therapy. Despite the challenges, advancements in technology and increased awareness among healthcare professionals are enhancing the efficiency of pharmacovigilance. Continued efforts to improve ADR reporting and monitoring will

ultimately contribute to safer and more effective drug use.

REFERENCES

[1]. World Health Organization. International drug monitoring: The role of national centres. Tech Rep Ser. 1972;(498):1-25.
[2]. Edwards IR, Aronson JK. Adverse drug reactions: Definitions, diagnosis, and management. Lancet. 2000;356(9237):1255-1259.
[3]. Aronson JK, Ferner RE. Clarification of terminology in drug safety. Drug Saf. 2005;28(10):851-870.
[4]. Rawlins MD, Thompson JW. Mechanisms of adverse drug reactions. In: Davies DM, ed. Textbook of Adverse Drug Reactions. 4th ed. Oxford: Oxford University Press; 1991:18-45.
[5]. Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18,820 patients. BMJ. 2004;329(7456):15-19.
[6]. Davies EC, Green CF, Taylor S, et al. Adverse drug reactions in hospital in-patients: a prospective analysis of 3695 patient-episodes. PLoS One. 2009;4(2).
[7]. Gell PGH, Coombs RRA. The classification of allergic reactions underlying disease. In: Coombs RRA, Gell PGH, eds. Clinical Aspects of Immunology. 3rd ed. Oxford: Blackwell; 1975:761-781.
[8]. Ingelman-Sundberg M. Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. Trends Pharmacol Sci. 2004;25(4):193-200.
[9]. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998;279(15):1200-1205.
[10]. Bates DW, Cullen DJ, Laird N, et al. Incidence of adverse drug events and potential adverse drug events: implications for prevention. JAMA. 1995;274(1):29-34.
[11]. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487-497.
[12]. World Health Organization. The importance of pharmacovigilance: safety monitoring of medicinal products. 2002. Geneva: World Health Organization.
[13]. Talbot JC, Nilsson BS. Pharmacovigilance in the pharmaceutical industry. Br J Clin Pharmacol. 1998;45(5):427-431.
[14]. Olsson S. The need for global pharmacovigilance. Indian J Pharmacol. 2008;40(Suppl 1).
[15]. Uppsala Monitoring Centre. WHO Programme for International Drug Monitoring. Available from: https://www.who-umc.org/global-pharmacovigilance/who-programme/
[16]. Lindquist M. VigiBase, the WHO Global ICSR Database System: Basic Facts. Drug Inf J. 2008;42(5):409-419.
[17]. European Medicines Agency. Pharmacovigilance. Available from: https://www.ema.europa.eu/en/human-regulatory/overview/pharmacovigilance
[18]. Food and Drug Administration. MedWatch: The FDA Safety Information and Adverse Event Reporting Program. Available from: https://www.fda.gov/safety/medwatch
[19]. Pharmacovigilance Programme of India (PvPI). Central Drugs Standard Control Organization (CDSCO). Available from: https://cdsco.gov.in/opencms/opencms/en/Pharmacovigilance/
[20]. Hazell L, Shakir SA. Under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2006;29(5):385-396.
[21]. Montastruc JL, Sommet A, Lacroix I, et al. Pharmacovigilance for evaluating adverse drug reactions: value, organization, and methods. Therapie. 2006;61(5):439-446.
[22]. Sultana J, Cutroneo P, Trifirò G. Clinical and economic burden of adverse drug reactions. J PharmacolPharmacother. 2013;4(Suppl 1).
[23]. Harpaz R, Callahan A, Tamang S, et al. Text mining for adverse drug events: the promise, challenges, and state of the art. Drug Saf. 2014;37(10):777-790.
[24]. Rozenblum R, Bates DW. Patient-centred healthcare, social media and the internet: the perfect storm? BMJ Qual Saf. 2013;22(3):183-186.
[25]. Ghosh S, Acharya LD, Rao PG, et al. Adverse drug reactions in elderly patients of a tertiary care teaching hospital in India: a retrospective study. Indian J Pharmacol. 2006;38(4):251-254.

[26]. Ramesh M, Parthasarathi G. Adverse drug reactions reporting: attitudes and perceptions of medical practitioners. Asian J Pharm Clin Res. 2009;2(2):10-14.
[27]. Palaian S, Ibrahim MI, Mishra P. Health professionals' knowledge, attitude and practices towards pharmacovigilance in Nepal. Pharm Pract (Granada). 2011;9(4):228-235.
[28]. Varallo FR, Planeta CS, de Carvalho Mastroianni PC. Effectiveness of pharmacovigilance: multifaceted educational intervention related to the knowledge, skills, and attitudes of multidisciplinary hospital staff. J Eval Clin Pract. 2017;23(5):1008-1015.